Skip to main navigation Skip to search Skip to main content

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters

  • Geraldine Nouailles
  • , Julia M. Adler
  • , Peter Pennitz
  • , Stefan Peidli
  • , Luiz Gustavo Teixeira Alves
  • , Morris Baumgardt
  • , Judith Bushe
  • , Anne Voss
  • , Alina Langenhagen
  • , Christine Langner
  • , Ricardo Martin Vidal
  • , Fabian Pott
  • , Julia Kazmierski
  • , Aileen Ebenig
  • , Mona V. Lange
  • , Michael D. Mühlebach
  • , Cengiz Goekeri
  • , Szandor Simmons
  • , Na Xing
  • , Azza Abdelgawad
  • Susanne Herwig, Günter Cichon, Daniela Niemeyer, Christian Drosten, Christine Goffinet, Markus Landthaler, Nils Blüthgen, Haibo Wu, Martin Witzenrath, Achim D. Gruber, Samantha D. Praktiknjo, Nikolaus Osterrieder, Emanuel Wyler, Dusan Kunec, Jakob Trimpert
  • Charité – Universitätsmedizin Berlin
  • Free University of Berlin
  • Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • Paul-Ehrlich-Institut
  • German Center for Infection Research
  • Cyprus International University
  • Humboldt University of Berlin
  • Chongqing University
  • City University of Hong Kong

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)

Abstract

Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
Original languageEnglish
Pages (from-to)860-874
Number of pages15
JournalNature Microbiology
Volume8
Issue number5
DOIs
Publication statusPublished - 1 May 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters'. Together they form a unique fingerprint.

Cite this